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Abstract
Tuberculosis (TB) is a leading cause of mor-
bidity and mortality worldwide, accounting for
about 9.6 million new cases and 1.5 million
deaths annually. The poorest and socially
excluded groups carry the largest burden of
disease, which makes it essential to properly
address the social determinants of health
through poverty reduction measures and tar-
geted interventions on high-risk populations.
The spread of multidrug-resistance TB
requires special attention and highlights the
need to foster research on TB diagnostics, new
drugs and vaccines. Although many advances
have been made in the fight against TB over
the last twenty years, a lot is still needed to
achieve global elimination. The new end-TB
strategy that was first launched in 2014 by the
World Health Organization, is fully in line with
the seventeen Sustainable Development Goals
that came into effect since January 2016 and
sets ambitious goals for the post-2015 agenda.
A 90% reduction in TB-related mortality and an
80% decline in TB incidence within 2030 as
well as the abolition of catastrophic expendi-
tures for TB-affected people are the main tar-
gets of this strategy. Strong government com-
mitment and adequate financing from all
countries together with community engage-
ment and appropriate investments in research
are necessary in order to reach these objec-
tives. 
Introduction
In 2016, tuberculosis (TB) is still a major
cause of death and suffering worldwide. Its
control is a global public health issue and
therefore needs to be conceived and carried
out along with the basic principles of equity,
human right to health and social protection. As
marginalized people are always greatly
exposed to health problems and often face dif-
ficulties in accessing care, social and econom-
ic determinants of ill health must be appropri-
ately addressed together with adequate imple-
mentation of the specific interventions avail-
able today to combat those diseases that dis-
proportionally affect the poorest. Similarly to
what observed for other infectious diseases,
TB epidemiology is closely connected with
social and economic conditions which makes
TB prevention, care and control even more
challenging.1 Poverty reduction has been rec-
ognized as a global priority by the United
Nations and other International Organizations
since many decades, but it was only when the
Millennium Development Goals (MDGs) were
first launched in 2000 that this issue was actu-
ally put in the spotlight. The MDGs, in short,
called upon all governments to join forces to
combat poverty and its consequences, includ-
ing health conditions like TB, in order to foster
development of societies and nations. In this
context, community engagement played a piv-
otal role in reaching the most vulnerable
groups, assessing their specific needs and pro-
moting active mobilization of society.
In this paper we will discuss the main
aspects of TB epidemiology at global level as
well as the threat of multidrug resistances.
Current achievements, future challenges, and
prevention and control strategies in the con-
text of the new Sustainable Development Goals
(SDGs) will also be examined. 
The global burden of tuberculosis
Tuberculosis ranks alongside HIV/AIDS as
the top infectious killer worldwide, with 9.6
million new incident cases and 1.5 million
deaths estimated to have occurred in 2014.2 Of
note, more than two thirds of the global TB
burden is reported in Africa and Asia, and in
absolute terms India, Indonesia and China
account for the highest number of TB cases
amounting to 43% of the global burden. 
The human immunodeficiency virus (HIV)
is the strongest risk factor for TB, and TB is
the first cause of death among people living
with HIV (PLHIV), even in an era of scale up of
antiretroviral therapy (ART), causing one third
of all HIV-related deaths. In 2014, HIV-infected
persons accounted for 1.2 million (12%) of the
estimated 9.6 million people globally who
developed TB. At the end of the same year, TB
contributed to one third of the 1.2 million
deaths from HIV/AIDS and HIV was responsible
for 25% of the 1.5 million TB deaths.2 The
majority (nearly three quarters) of these esti-
mated HIV-associated TB cases and deaths are
in the African Region, with eastern and south-
ern African countries carrying most of the
global burden. ART coverage among known
HIV-infected TB patients in 2014 was 77%,
which represents a further increase from pre-
vious years, but it is still far from the World
Health Organization (WHO) recommendation
that all HIV-positive people with TB should
receive it.3,4 Other co-morbidities such as those
related to diabetes mellitus, smoking, and alco-
hol abuse are currently emerging in high, mid-
dle and low-income countries as potentially
associated with a greater risk of progression
from latent TB infection (LTBI) to active dis-
ease (two to three-fold higher in diabetics and
smokers, for instance) as well as a less favor-
able treatment outcome.5
Multidrug resistant tuberculosis (MDR-TB),
defined as resistance to, at least, rifampin and
isoniazid (the most commonly used and potent
drugs of the currently recommended first-line
therapeutic regimen), represents another
important threat in the fight against the dis-
ease. The emergence and spread of drug
resistances mostly derive from mismanage-
ment of TB cases such as the use of inappro-
priate dosages, inappropriate regimens, limit-
ed availability of quality-assured pharmaceuti-
cal products, and little efforts to support
patient’s adherence. Approximately 480,000
newly emerging cases of MDR-TB are estimat-
ed to occur every year. However, the proportion
of cases detected and notified is only about a
quarter of those estimated due to low imple-
mentation of drug susceptibility testing espe-
cially in resource-limited settings. The distri-
bution of MDR-TB cases is geographically
uneven (Figure 1), with countries of the for-
mer Soviet Union reporting the highest per-
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centages (up to 35%) and five countries
(India, China, Russia, Pakistan and Ukraine)
accounting for as much as 60% of the global
caseload in absolute terms.2
Achievement of global targets
In September 2000 the United Nations
General Assembly adopted an historical resolu-
tion, best known as the Millennium
Declaration.6 This sent a strong signal to all
countries and communities in an attempt to
change their behaviors, socio-political choices
and health responses based on the fundamen-
tal principles of freedom, equality, solidarity,
tolerance, respect for nature and shared
responsibility. Eight goals to be achieved with-
in the following fifteen years were identified.
Three of them were devoted to health issues,
and MDG 6 specifically addressed the three
global epidemics of HIV/AIDS, malaria and TB.
In particular, the TB-relevant target as defined
in the MDG framework was to halt and begin to
reverse the incidence by 2015. This target has
been achieved both globally and in all six WHO
Regions, with 43 million lives estimated to
have been saved between 2000 and 2014
(Figure 2). Through effective prevention, qual-
ity-assured diagnosis and proper treatment the
burden of TB has therefore decreased.7
Additionally, a 47% drop in TB mortality rates
has been estimated since 1990, which means
that the international goal of mortality reduc-
tion has almost been met. However, incidence
is falling too slowly, with a 1.5% per year
declining rate, which is far from sufficient to
reach the future targets. Importantly, while an
average 86% cure rate has been attained at
global level among new TB cases, some coun-
tries, like those in Eastern Europe, have docu-
mented much lower treatment success due to
the high prevalence of MDR-TB. With respect
to TB/HIV co-infection, assessment of achieve-
ments shows that significant progress has
been made through the implementation of
TB/HIV collaborative activities since 2005, with
an estimated over 5 million lives saved up to
now. 
The challenges of tuberculosiscontrol
If we look at the future challenges of TB con-
trol, five priorities for action can be delineated. 
First of all, around 3.6 million TB cases are
estimated to be missing every year comparing
with the estimated figure; this means that they
are not diagnosed and/or notified to public
health systems.8 All such unknown cases may
be diagnosed and treated but not reported, or
simply never detected. This constitutes both an
individual care and a transmission problem, as
their outcomes may not be favorable and they
may be responsible for continuous transmis-
sion thus representing a major public health
concern. 
Secondly, MDR-TB must be addressed as a
crisis given its potential for hindering the
achievement of current objectives. Newly
available rapid molecular diagnostics need to
be expanded at the lowest possible care level
and new medicines, such as bedaquiline and
delamanid, added to current regimens to
improve care of drug-resistant cases and pre-
vent them from spreading further.9
Third, the co-epidemic of TB/HIV requires
an accelerated response based on a deeper and
more comprehensive integration of services
between often separately managed programs.10
The Global Fund and other key stakeholders
have expressed concerns about the limited
coverage of collaborative TB/HIV activities
within grants of the Global Fund and other ini-
tiatives, and called for measures for improve-
ment. This has led to the development of uni-
fied concept notes (i.e., proposals by countries
applying for external financing) aimed to bet-
ter address the dual epidemic through a more
service-integrated approach.11
Fourth, financial support to the fight against
TB is pivotal to close the resource gap. About 8
billion US$ are annually required to cover the
ordinary costs of case detection and treatment
worldwide, but available funds, in the range of
6.4 billion US$, are not enough to address such
needs (Figure 3).2
Last but not least, research needs to be
intensified along the entire spectrum from
basic towards the development pipelines and
operational research, in order to successfully
result in new diagnostics, drugs and eventually
vaccines and the rapid uptake of such innova-
tions. To this purpose, new investments from
research institutions, governments and the
corporate sector need to fill a gap that is esti-
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Figure 1. Percentage of new tuberculosis cases with MDR-T/B, 2015. Reproduced with
permission from Global Tuberculosis Report 2015, WHO.2
Figure 2. Trends in tuberculosis incidence (the red line refers to incident cases among
HIV-infected persons), prevalence and mortality, 1990-2015. Reproduced with permis-
sion from Global Tuberculosis Report 2015, WHO.2
No
n c
om
me
rci
al 
us
e o
nly
                                   [Infectious Disease Reports 2016; 8:6570]                                                     [page 35]
mated to be in the area of at least 1.3 billion
US$ (Figure 3).
The future response to tuber-culosis challenges
The future response to the challenges out-
lined above is included in a new set of seven-
teen Sustainable Development Goals (SDGs)
that were recently launched within the post-
2015 global development agenda to come into
effect on January 1st, 2016 when they will
replace the MDGs.12 One of the main differ-
ences between SDGs and MDGs lies in the fact
that the former ones are universally applied to
all countries instead of being focused on the
developing world and depending largely upon
aid funding. In addition, while the MDGs were
limited to some well-defined categorical chal-
lenges to face, the SDGs are much broader in
their reach, are integrated and indivisible, and
rely not only on economic but also on environ-
mental, moral and political considerations.
Among the SDGs, Goal 3 (ensure healthy lives
and promote well-being for all at all ages) cov-
ers a range of health-related issues such as
maternal and child health, communicable and
non-communicable diseases, and target 3.3
clearly calls for ending the major global epi-
demics (HIV, TB, malaria, neglected tropical
diseases) by 2030.13 This is fully in line with
what stated in May 2014 by the 67th World
Health Assembly through a resolution that con-
tains the new global WHO’s End TB Strategy
and its ambitious targets.14 The vision behind
the new strategy is a TB-free world, with no
more people suffering from the disease or
dying because of it. Targets for 2035 include a
95% decline in TB mortality, a 90% reduction
in TB incidence rate (to less than 10 cases per
100,000 population globally) and, to align with
the quest for universal health coverage and
social protection, the complete abolition of cat-
astrophic expenditures for TB-affected people
and families. Broad poverty alleviation meas-
ures are therefore strongly expected to effec-
tively overcome the impediments and cut down
the barriers in access to healthcare.15,16
Furthermore, some milestones have been
introduced every five years along the pathway
up to 2035: in particular, coinciding with the
SDG deadline of 2030, the number of TB
deaths should be reduced by 90% and TB inci-
dence rate should decline by 80%, compared to
the baseline at 2015, by 2030. Of note, there is
an additional high-level target of zero cata-
strophic costs that should be achieved already
in 2020.17
The END-TB strategy
The new strategy stands on three pillars and
is based on four cross-cutting principles
defined as follows: i) government stewardship
and accountability, with monitoring and evalu-
ation; ii) building a strong coalition with civil
society and communities; iii) protecting and
promoting human rights, ethics and equity; iv)
adaptation of the strategy and targets at coun-
try level, with global collaboration (Table 1).14
The first pillar focuses on care aspects that
are specific to TB. It refers to integrated,
patient-centered care and prevention, and
underlines the need to clearly identify the
most vulnerable groups in a population in
order to address their needs as a priority.
Active case finding along with drug suscepti-
bility testing for resistance detection are
among the core components of this pillar as
are the concepts of treatment for all, including
drug-resistant cases and children. Special
attention is also devoted to PLHIV, given their
high-risk condition, which claims for tailored
interventions involving the provision of com-
bined treatments for both diseases as well as
the implementation of appropriate preventive
measures. Finally, preventive therapy to be
administered to people at high risk is empha-
sized as a tool to prevent disease among the
pool of latently infected people.
The second pillar calls for bold policies and
supportive systems to be based on a strong
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Table 1. End tuberculosis strategy: vision, targets and pillars and principles.
Vision                                   A world free of TB (zero deaths, disease and suffering due to tuberculosis)
Goal                                      End the global TB epidemic
Targets for 2035                 95% reduction in TB deaths (compared with 2015); 90% reduction in TB incidence rate (less than 100 TB cases per million 
                                              population); no affected families facing catastrophic costs due to TB
Principles                            Government stewardship and accountability, with monitoring and evaluation; strong coalition with civil society organizations and 
                                              communities; protection and promotion of human rights, ethics and equity; adaptation of the strategy and targets at country level, 
                                              with global collaboration.
Pillars and components   Integrated, patient-centred care and prevention: i) early diagnosis of tuberculosis including universal drug susceptibility testing, 
                                              and systematic screening of contacts and high-risk groups; ii) treatment of all people with tuberculosis including drug-resistant
                                              tuberculosis, and patient support; iii) collaborative tuberculosis/HIV activities, and management of co-morbidities; iv) preventive
                                              treatment of persons at high-risk, and vaccination against tuberculosis.
                                              Bold policies and supportive systems: i) political commitment with adequate resources for tuberculosis care and prevention; ii)
                                              engagement of communities, civil society organizations, and public and private care providers; iii) universal health coverage policy;
                                              and regulatory frameworks for case notification, vital registration, quality and rational use of medicines, and infection control; iv)
                                              social protection, poverty alleviation and actions on other determinants of tuberculosis.
                                              Intensified research and innovation: i) discovery, development and rapid uptake of new tools, interventions, and strategies; ii)
                                              research to optimize implementation and impact, and promote innovations.
Adapted with permission from WHO, 2015.14 
Figure 3. Tuberculosis financing and funding gaps, 2014. Adapted with permission from
Global Tuberculosis Report 2015, WHO.2
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political commitment, greater financing,
extended community engagement, active coop-
eration with non-governmental organizations
as well as the civil society and public and pri-
vate institutions. Universal health coverage
and social protection represent the corner-
stones of the post-2015 broader agenda for
effective health systems delivering the neces-
sary services to people. Although it is essential
that TB diagnosis and treatment are provided
free of charge to all people irrespective of their
living area, other costs such as those related to
travel to reach the healthcare facilities or
those produced by the loss of working days
must be taken into account to properly define
the financial consequences of TB on affected
patients.18 This pillar also emphasizes the
broader policies that must be in place for any
disease control effort to succeed.
The third pillar underlines the importance
of intensified research and innovation to make
a real change in current TB trends. In order to
achieve the ambitious targets of the End-TB
strategy, the rate of decline of global TB inci-
dence must increase to at least 10% per year by
2015. Similar declining rates were reached in
some European countries in the mid twentieth
century, following the introduction of the first
anti-TB drugs compounded with the signifi-
cant improvement of general living conditions.
The development of better diagnostics (includ-
ing new point-of-care tests), safer, easier and
shorter treatment regimens for active TB and
LTBI, and effective pre- and post-exposure vac-
cines are critical to break the trajectory of the
TB epidemic and further accelerate the reduc-
tion of TB incidence after 2025. Without new
effective tools it will not be possible to acceler-
ate incidence decline at 17% per year, which is
necessary to achieve the 2035 targets.19,20
Tuberculosis research: what isneeded?
New diagnostic tools are particularly await-
ed in order to improve the diagnosis of disease
and latent infection, the rapid detection of
drug-resistance, and for use in the pediatric
population. Several new diagnostics or diag-
nostic methods have been endorsed by the
WHO since 2007 and many others are under
investigation. Whole-genome sequencing is
being studied in an attempt to identify relevant
mutations that could predict drug resistance:
this approach may be potentially useful togeth-
er with routine diagnostic tests in order to
build up individualized therapeutic schemes in
severe cases of MDR-TB and extensively drug-
resistant TB (XDR-TB).21 A number of new
molecules are currently in the early phases of
the development pipeline although it will prob-
ably take about a decade to put them into the
market, provided that their efficacy and safety
will be demonstrated.22,23 After many years of
financially limited research, two new drugs for
MDR-TB (bedaquiline and delamanid) were
approved between 2012 and 2013. These two
drugs may save lives although they will proba-
bly yield a little impact of the global epidemiol-
ogy of TB for which shorter and more effective
regimens for both drug-susceptible disease
and latent infection are necessary.23-25
Vaccines may eventually be the most effective
response to TB but the development of effec-
tive vaccines is considerably hindered by the
complex biology of mycobacteria, whose
nature is still partially undefined.26,27 BCG,
which was first introduced in 1921, is the only
currently available vaccine, mostly unsuitable
for preventing infection and TB disease and
therefore with limited use in specific contexts
and for specific target populations (such as
children in the first 2-3 years of life where it
prevents wide dissemination of bacilli follow-
ing exposure).28,29
Concluding remarks
Looking beyond 2015, ending the TB epi-
demic is one of the best returns in invest-
ments. As recently highlighted in The
Economist (Development: the economics of
optimism; issued on Jan 24, 2015), reducing
the deaths from tuberculosis would allow to
gain an average 43 US dollars per dollar spent.
Lowering the burden of this disease therefore
represents a high-impact and cost-effective
poverty alleviation measure, more than many
other health interventions, which is consistent
with the close linkages existing between TB
and impoverishment. 
Although the MDG target of reversing trends
in TB epidemiology has been met, the global
burden remains enormous with several chal-
lenges that need to be properly addressed: we
can and we definitely have to do more in TB
control. Global elimination in the next few
decades can eventually come true in spite of
the long and hard way towards it.
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